Flora Growth Corp. FLGC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
29/100
Developing

About Flora Growth Corp.

Flora Growth Corp. operates as an AI-powered asset management company focused on providing decentralized AI. In addition, it engages in the distribution of pharmaceutical goods and medical cannabis products to treat a range of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. Flora Growth Corp. was incorporated in 2019 and is headquartered in Fort … Full FLGC analysis →

Competitive advantage assessment

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.84), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 15.0th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 3.7th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
19

Where FLGC ranks in Drug Manufacturers - Specialty & Generic

Flora Growth Corp. ranks #67 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 74%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near FLGC in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
63 Assertio Holdings, Inc. ASRT 32/100 Developing
64 Sunshine Biopharma Inc. warrant SBFMW 31/100 Developing
65 Sunshine Biopharma Inc. SBFM 31/100 Developing
66 China Pharma Holdings, Inc. CPHI 29/100 Developing
67 Flora Growth Corp. FLGC 29/100 Developing
68 Avadel Pharmaceuticals plc AVDL 27/100 Developing
69 Citius Oncology, Inc. CTOR 27/100 Developing
70 Aquestive Therapeutics, Inc. AQST 26/100 Developing
71 China SXT Pharmaceuticals, Inc. SXTC 26/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How FLGC scores on the Corporate Default defenses

Pricing Power

Score 19 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 46 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 33 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 11 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 24 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 47 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding FLGC's moat

What is Flora Growth Corp.'s moat score?

Flora Growth Corp. (FLGC) scores 29 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #67 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 74%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (47/100) and its weakest is Capital Efficiency (11/100).

How does Flora Growth Corp. compare with other Drug Manufacturers - Specialty & Generic companies?

Flora Growth Corp. ranks #67 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are China Pharma Holdings, Inc. (CPHI) at 29 just above it and Avadel Pharmaceuticals plc (AVDL) at 27 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Flora Growth Corp. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Flora Growth Corp.?

The Corporate Default template measures 6 defenses, and FLGC scores: Pricing Power (19), Cost Advantage (46), Customer Stickiness (33), Capital Efficiency (11), Resilience (24), Scale & Market Position (47). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000